Immatics NV (IMTX)
11.02
-0.26
(-2.30%)
USD |
NASDAQ |
May 31, 16:00
11.02
0.00 (0.00%)
After-Hours: 20:00
Immatics Cash from Financing (TTM): 282.13M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 282.13M |
December 31, 2023 | 91.50M |
September 30, 2023 | 205.19M |
June 30, 2023 | 153.07M |
March 31, 2023 | 130.31M |
December 31, 2022 | 130.46M |
September 30, 2022 | 17.65M |
Date | Value |
---|---|
June 30, 2022 | 14.73M |
March 31, 2022 | -3.284M |
December 31, 2021 | -3.092M |
September 30, 2021 | -7.908M |
June 30, 2021 | 237.07M |
March 31, 2021 | 237.50M |
December 31, 2020 | 237.41M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-7.908M
Minimum
Sep 2021
282.13M
Maximum
Mar 2024
123.05M
Average
130.39M
Median
Cash from Financing (TTM) Benchmarks
MorphoSys AG | -- |
Affimed NV | -6.734M |
InflaRx NV | 57.24M |
BioNTech SE | -538.52M |
CureVac NV | -3.340M |